Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
56.44
+0.44 (0.79%)
May 8, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Xenon Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $70.55, which forecasts a 25.00% increase in the stock price over the next year. The lowest target is $47 and the highest is $97.
Price Target: $70.55 (+25.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 4 | 4 | 3 |
| Buy | 6 | 6 | 7 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $80 → $82 | Buy | Maintains | $80 → $82 | +45.29% | May 8, 2026 |
| Needham | Needham | Strong Buy Maintains $80 → $78 | Strong Buy | Maintains | $80 → $78 | +38.20% | May 8, 2026 |
| Wedbush | Wedbush | Buy Maintains $64 → $63 | Buy | Maintains | $64 → $63 | +11.62% | Mar 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $49 → $68 | Buy | Maintains | $49 → $68 | +20.48% | Mar 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $47 → $64 | Buy | Maintains | $47 → $64 | +13.39% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
4.15M
from 7.50M
Decreased by -44.65%
Revenue Next Year
107.78M
from 4.15M
Increased by 2,496.48%
EPS This Year
-4.86
from -4.36
EPS Next Year
-4.71
from -4.86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.3M | 441.5M | ||||||
| Avg | 4.2M | 107.8M | ||||||
| Low | n/a | 13.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 250.0% | 10,536.7% | ||||||
| Avg | -44.7% | 2,496.5% | ||||||
| Low | - | 230.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -4.68 | -0.58 | ||||||
| Avg | -4.86 | -4.71 | ||||||
| Low | -5.10 | -5.95 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.